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Background: Changing US demographics and evolving chronic hepatitis
B (CHB) treatments may affect longitudinal trends in CHB-related
complications. We studied trends in the prevalence of cirrhosis (past or
present) and incidence of all-cause mortality, stratified by patient age, sex,
race, and antiviral treatment status, in a sample from US health care
systems.
Methods: Joinpoint and Poisson regression (univariate and multi-
variable) were used to estimate the annual percent change in each
outcome from 2006 to 2016.
Results: Among 5528 CHB patients, cirrhosis prevalence (including
decompensated cirrhosis) rose from 6.7% in 2006 to 13.7% in 2016;
overall mortality was unchanged. Overall rates of cirrhosis and mor-
tality were higher among treated patients, but adjusted annual percent
changes (aAPC) were significantly lower among treated than untreated
patients (cirrhosis: aAPC +2.4% vs. +6.2%, mortality: aAPC −3.9%
vs. +4.0%). Likewise, among treated patients, the aAPC for mortality
declined −3.9% per year whereas among untreated patients, mortality
increased +4.0% per year.
Conclusions: From 2006 to 2016, the prevalence of cirrhosis among
CHB patients doubled. Notably, all-cause mortality increased
among untreated patients but decreased among treated patients.
These results suggest that antiviral treatment attenuates the pro-
gression of cirrhosis and the risk of death among patients
with CHB.
Key Words: cirrhosis prevalence, decompensated cirrhosis, hep-
atocellular carcinoma, liver transplant, joinpoint modeling, HCC
(J Clin Gastroenterol 2021;00:000–000)
P atients with chronic hepatitis B (CHB) infection are at riskof a number of serious long-term outcomes—including
cirrhosis and liver-related mortality.1 Although these outcomes
are well-described by natural history studies2,3 and point-
prevalence studies within defined cohorts,4,5 there are
remarkably few longitudinal analyses of trends in CHB-related
cirrhosis and mortality—and none in the United States.
CHB prevention and treatment strategies have changed
dramatically in the past several decades, with universal hepatitis
B vaccination campaigns preventing new infections and the
emergence of highly effective antiviral treatment regimens
reducing sequelae from chronic infections. At the same time,
some of the well-known drivers of CHB epidemiology in the
United States—including an aging US population, migration
from regions where CHB is endemic, and continued challenges
in widespread screening and access to treatment—likely
attenuate some of those positive gains. Antiviral treatment is
not recommended for all CHB patients; indications vary by
viral load, host immune status, and severity of the liver disease.
Emerging evidence, however, suggests that liver fibrosis may
progress even among patients with low-level viremia who may
not meet thresholds for treatment6; even among these patients,
however, antiviral treatment can reduce risks of complications,
such as hepatocellular carcinoma.7
Changing US demographics may affect longitudinal trends
in CHB-related complications. The Chronic Hepatitis Cohort
Study (CHeCS) includes over 5000 CHB patients receiving care
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at one of 4 large health systems with a combined population of
over 2 million adult patients. Because CHeCS comprises a geo-
graphically and racially diverse sample of “real world” patients
receiving routine clinical care, it is broadly generalizable to CHB
patients throughout the US.8 We used comprehensive medical
record data and our validated serum and clinical markers for
cirrhosis identification to investigate the impact of age, race, sex,
and treatment status on trends in prevalence of cirrhosis and
incidence of mortality among CHB patients from 2006 to 2016.
METHODS
CHeCS includes patients aged 18 years and above who
received health care services on or after January 1, 2006 at one
of 4 health care systems—Henry Ford Health System
(HFHS), Detroit, MI; Geisinger Health System (GHS),
Danville, PA; Kaiser Permanente Northwest (KPNW), Port-
land, OR; and Kaiser Permanente Hawai’i (KPHI), Honolulu,
HI. The study follows all guidelines of the US Department of
Health and Human Services (HHS) regarding the protection
of human subjects; the CHeCS protocol was approved and
is renewed annually by the institutional review board at each
of the 4 sites. Due to the deidentified nature of this observa-
tional study, requirements for written informed consent were
waived.
CHeCS methods have been described elsewhere.8,9
Briefly, CHeCS has a comprehensive data collection system
based on electronic health records. Patients are identified
electronically using a combination of laboratory and Inter-
national Classification of Disease (ICD) 9 and 10–based
criteria; CHB is subsequently confirmed through chart
abstraction.8 CHeCS uses a “dynamic” sampling design; for
each data collection cycle, a random sample of new patients
is added to the cohort, while existing patients continue to be
followed, this method allows us to generalize our findings to
other populations. Retrospective patient data are captured
through the early 1990s (when available), and data have
been collected prospectively through December 31, 2016.
Identification of Cirrhosis
CHeCS has previously validated the use of the Fibrosis-4
(FIB4) serum-based biomarker in CHB patients; we found that
a FIB4 score > 5.17, calculated from routine laboratory
results, accurately classifies cirrhosis (Metavir fibrosis stage F4;
area under the receiver operator characteristic curve=88%;
and positive predictive value=82%) in patients with CHB.10
We have also developed an electronic diagnosis code-based
Classification and Regression Tree model to identify decom-
pensated cirrhosis. An algorithm using 5 liver-related clusters
yielded an area under the receiver operator characteristic curve
of 92% and positive predictive value of 85%.11 Due to the
observational nature of this study, availability of cirrhosis data
varied. Among all confirmed CHB patients, fewer than 10%
had liver biopsy data; laboratory data for calculation of FIB4
were available for roughly 60% of patients. To overcome this
variation, we implemented a hierarchical classification algo-
rithm to identify presence of cirrhosis during a given year:
(1) classification of decompensated cirrhosis using the Classi-
fication and Regression Tree model; (2) “F4” liver biopsy
determination, or transient elastography >11.012; (3) FIB4>
5.17; (4) presence of ICD-9/10 diagnosis codes for cirrhosis in
the medical record. Cirrhosis was assumed to persist in fol-
lowing years unless records indicated receipt of a liver trans-
plant. This algorithm was used consistently for determination
of cirrhosis across the study period.
Incidence of All-cause Mortality
We used all-cause mortality rather than liver-related
mortality because our previous work has shown that liver-
related mortality is underreported in real world settings,
particularly among patients with CHB.13
Statistical Analysis
We examined the prevalence of past or present cir-
rhosis (including decompensated cirrhosis) and incidence of
all-cause mortality, among CHeCS CHB patients for each
successive year during the 2006-2016 period. For the pur-
pose of computing prevalence and incidence rates for each
year, patients were included in the CHB population for any
given year if they had been diagnosed with CHB before or
during the given year and their last encounter was during or
after the given year. CHB/hepatitis C coinfected patients
were excluded; CHB/human immunodeficiency virus coin-
fected patients were included in analyses.
Outcomes of interest included prevalence of past or
present cirrhosis, and incidence of all-cause mortality.
Covariates of interest included: age during the given year
(categorized as below 30, 30 to below 40, 40 to below 50, 50
to below 60, and 60 and above); sex; and race [categorized
as black/African American, Asian American/American
Indian/Pacific Islander (AAPI), white, and other/unknown].
A categorical age variable was used to assess the effect of
aging within the cohort. Antiviral treatment status (ever
treated vs. never treated) was included as a covariate due to
its recognized impact on risk of progression of liver
disease.14 We note, however, that interpretation of this
variable with regard to trends in cirrhosis prevalence should
be undertaken with caution; antiviral treatment is not uni-
versally recommended for CHB patients and presence of
cirrhosis may itself be an indication for treatment. We
performed a propensity score–adjusted sensitivity analysis to
further test the effect of antiviral treatment on mortality,
which may be impacted by the presence of cirrhosis.
We adapted and extended a 2-step joinpoint Poisson
regression modeling approach15 to study change in prev-
alence in cirrhosis and incidence of all-cause mortality
over time. Joinpoint regression analysis involves fitting a
series of joined straight lines on a log scale to the trend;
each joinpoint represents a statistically significant
(P< 0.05) change in trend (ie, the slope of the line seg-
ment). In the first step, we identified the optimal joinpoint(s)
using a nonlinear modeling approach. For example, a
single joinpoint splits the trend line into 2 segments,
whereas a lack of joinpoints indicates that the best fit to the
trend consists of only a single line segment. The unadjusted
annual percent change (APC) [(rate of current year−rate
of previous year)/rate of previous year] was estimated for
each segment line and tested compared with no change
(APC= 0).
Next, multivariable analyses were performed based on
the selected joinpoint(s) as well as the possible stratification
variables, considering possible variable-by-trend (time)
interactions. Variables were retained in the final model if
they were significant or there were significant variable-by-
time interactions at the level of 0.05. The adjusted annual
percent changes (aAPCs) and 95% confidence intervals (CIs)
for segment lines were also calculated using multivariable
modeling; analyses were adjusted for all covariates/variable-
by-time interactions retained in the model. A significant
variable-by-time interaction indicated that APCs differed by
variable category. From the same multivariable model, rate
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ratios (RRs) were estimated to compare differences in rates
between variable categories (eg, race). We did not use age-
standardized rates in the model for aAPC estimation; this is
consistent with the approach used in a recent study of trends
of cirrhosis prevalence in specific subpopulations among US
veterans with CHB.16 However, age at a given year was included
as a stratification variable in the model. Analyses were performed
for each outcome of interest using SAS, version 9.4 (SAS Institute
Inc., Cary, NC).
RESULTS
Across the entire 2006–2016 study period, we identified a
total of 5528 confirmed CHB patients, with 952 cases of any
cirrhosis [17%; including 401 cases of decompensated cirrhosis
(7%)] and 628 deaths (11%). Cohort size increased across time—
from 2564 in 2006 to 3411 in 2016. The yearly distribution of
select patient demographics are presented in Table 1; a summary
for the entire study period is presented in Supplementary Table 1
(Supplemental Digital Content 1, http://links.lww.com/JCG/
A674). The proportion of female patients remained roughly
the same across the study period (45% to 48%). Consistent with
our previous report,17 the rate of antiviral treatment for CHB
rose from 20% in 2006 to 35% in 2016.
Prevalence of Cirrhosis (Past or Present)
Overall, the prevalence of cirrhosis (including decom-
pensated cirrhosis) doubled over the study period, from
6.7% in 2006 to 13.8% in 2016. No joinpoint was identified;
the multivariable model showed a single segment from 2006
to 2016, with unadjusted APC of +5.9% per year (P< 0.01;
Table 2). The multivariable model showed that sex, race,
and antiviral treatment status were associated with cirrhosis
prevalence (Fig. 1). There was a treatment-by-time
interaction—indicating that aAPC depended on treatment
status. Although overall cirrhosis prevalence was higher
among treated patients, aAPC was significantly lower, indi-
cating that rates of cirrhosis increased more slowly among
treated than untreated patients (+2.4% vs. +6.2% per year,
respectively).
Table 3 displays RR comparisons within sex, race, age,
and treatment status strata. Female patients had lower rates of
cirrhosis than male patients (RR=0.59; 95% CI: 0.55-0.64;
P<0.01) across the study period. Prevalence of any cirrhosis
was lower among African American patients than white
patients (RR=0.87; 95% CI: 0.80-0.95; P<0.01); rates among
AAPI patients were even lower, roughly half that of white
patients (RR= 0.54; 95% CI: 0.50-0.58; P< 0.01). There was a
quantitative treatment status-by-time interaction. In 2006,
prevalence of cirrhosis among treated patients was >4 times
that of untreated patients; by 2016, that ratio had decreased to
roughly 3-fold (2006: RR=4.55, 95% CI: 3.23-6.25; 2016:
RR=3.13, 95% CI: 2.56-3.70).
Incidence of All-cause Mortality
Overall all-cause mortality did not change significantly
across the study period, with rates of 1.4% in 2006 to 1.7%
in 2016 (Table 1); no joinpoint was identified. Sex, race, age,
and antiviral treatment status were retained in the final
multivariable model (Fig. 2). As with cirrhosis, lower rates
of mortality were observed among female (Table 3, RR=
0.68, 95% CI: 0.57-0.82, vs. male) and younger patients
(RRs were 43% to 93% lower among patients younger than
60 y compared with those 60 y or older). African Americans
had the highest rates of mortality, roughly 26% higher than
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AAPI/other patients had the lowest mortality (RR= 0.42,
95% CI: 0.34-0.51, compared with whites). A significant
treatment status-by-time interaction was observed. In 2006,
rates of mortality among treated patients were 3.5 times that
of untreated patients; by 2016, that ratio had decreased by
roughly half and was no longer significantly different
(treated vs. untreated in 2006: RR= 3.57 95% CI: 1.82-7.14;
in 2016, RR= 1.52 95% CI: 0.89-2.56). Treatment also
impacted the APC in all-cause mortality—among treated
patients, the aAPC for mortality declined −3.9% per year
whereas among untreated patients, mortality increased
+4.0% per year (Table 2).
In a sensitivity analysis evaluating whether cirrhosis
influenced the effect of antiviral treatment on all-cause mor-
tality, we used propensity scores to adjust for treatment
selection bias; covariates included age, sex, race, hepatitis B
e-antigen status, insurance, household income, and presence/
absence of cirrhosis. We saw that the effect of treatment on
mortality was influenced by presence of cirrhosis (P<0.001 for
treatment-by-cirrhosis interaction); among patients with cir-
rhosis, antiviral treatment was protective against risk of mor-
tality (hazard ratio=0.81; 95% CI: 0.67-0.99).
DISCUSSION
In a diverse “real world” cohort of over 5000 CHB
patients, we observed that overall prevalence of cirrhosis
doubled from 2006 to 2016, while incidence of all-cause
mortality remained flat across the study period. The rate of
treatment increased from 20.5% in 2006 to 35.4% in 2016;
receipt of antiviral medication was more common among
patients with cirrhosis, a finding that reflects current
guidelines to initiate treatment for patients with advanced
fibrosis. However, the relative increase in cirrhosis preva-
lence among treated patients was significantly lower than
among untreated patients (aAPC=+2.4% vs. +6.2%,
TABLE 2. Multivariable Trend Model: Adjusted APC in Rates of Complications Among Patients With Chronic Hepatitis B in Our Cohort
From 2006 Through 2016
Any Cirrhosis All-cause Mortality
APC APC (95% CI) P APC (95% CI) P
Unadjusted APC 5.9% (4.8-7.0) < 0.01 2.0% (−0.6 to 4.6) 0.13
Adjusted* APC
Ever treated 2.4% (1.1-3.7) < 0.01 −3.9% (−7.3 to −0.3) 0.03
No treatment 6.2% (4.5-8.1) < 0.01 4.0% (0.3-7.8) 0.035
*Adjusted analysis includes race, gender, and age-by-time interaction.
APC indicates annual percentage change; CI, confidence interval.
FIGURE 1. Prevalence of any cirrhosis by age, race, sex, and treatment status in patients with chronic hepatitis B in our cohort from 2006
to 2016. No joinpoint was identified. AAPI indicates Asian American/Pacific Islander.
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respectively). Furthermore, there was a significant treatment
status-by-time interaction for all-cause mortality. In 2006,
mortality was significantly higher among treated patients
than untreated patients; by 2016, that difference had nar-
rowed and became nonsignificant. This is reflected in aAPCs
for mortality, which decreased roughly 4% per year among
treated patients, but increased at a similar rate among
untreated patients. We also observed treatment status-by-
time interactions across the study period, with a slower
increase in cirrhosis and a decline in mortality among
treated patients, but the opposite among untreated patients.
Given that cirrhosis is an indication for initiation of anti-
viral treatment, receipt of treatment is in some cases a rough
proxy for disease severity. Our findings—slower increases in
cirrhosis prevalence and reductions in mortality among
treated patients—demonstrate the benefit of antiviral treat-
ment, even among CHB patients with more severe liver
disease.18,19 A sensitivity analysis also demonstrated that
antiviral treatment reduced mortality among patients who
were cirrhotic at baseline.
The implications of our findings relative to untreated
patients are rather complicated and less clear. Several studies
have suggested the benefits of treatment even among patients
with low-level viremia who do not necessarily meet the criteria
for treatment initiation.6 However, guidance regarding criteria
for treatment initiation reflects the complex physiological
TABLE 3. Multivariable Trend Model: Adjusted RRs for Comparisons by Sex, Race, and Age for Prevalence of Complications Among
Patients With Chronic Hepatitis B in Our Cohort From 2006 Through 2016
Cirrhosis* All-cause Mortality
Covariates Comparison RR (95% CI) P RR (95% CI) P
Sex Female vs. male 0.59 (0.55-0.64) < 0.01 0.68 (0.57-0.82) < 0.01
Race AAPI/other vs. white 0.54 (0.50-0.58) < 0.01 0.42 (0.34-0.51) < 0.011
African American vs. white 0.87 (0.80-0.95) < 0.01 1.26 (1.04-1.53) 0.02
Unknown vs. white 0.71 (0.62-0.81) < 0.01 0.71 (0.51-1.00) < 0.05
Age < 30 vs. ≥ 60 0.26 (0.23-0.30) < 0.01 0.07 (0.04-0.10) < 0.01
30 to <40 vs. ≥ 60 0.35 (0.31-0.38) < 0.01 0.13 (0.10-0.17) < 0.01
40 to <50 vs. ≥ 60 0.57 (0.52-0.62) < 0.01 0.26 (0.21-0.33) < 0.01
50 to <60 vs. ≥ 60 0.83 (0.76-0.91) < 0.01 0.57 (0.47-0.69) < 0.01
At 2006 Treated vs. untreated 4.55 (3.23-6.25) < 0.01 3.57 (1.82-7.14) < 0.01
At 2016 Treated vs. untreated 3.13 (2.56-3.70) < 0.01 1.52 (0.89-2.56) 0.12
*Includes compensated and decompensated cirrhosis.
AAPI indicates Asian American/Pacific Islander; CI, confidence interval; RR, rate ratio.
FIGURE 2. Incidence of all-cause mortality by age, race, sex, and treatment status with chronic hepatitis B in our cohort from 2006 to
2016. No joinpoint was identified. AAPI indicates Asian American/Pacific Islander.
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interaction between viral load and immune response in CHB.
Current recommendations prioritize patients with more severe
liver disease or higher levels of viral replication. Importantly,
there are many patients for whom treatment would be indicated,
but who do not receive treatment due to lack of access to
appropriate care.14 As shown in Table 1, a large but
decreasing proportion of our sample had never received
antiviral treatment—roughly 80% in 2006, which fell to 65% in
2016. It is beyond the scope of the current analysis to differentiate
between those patients for whom treatment was and was not
indicated under guidelines current during each study year.
Nonetheless, the significant increases in cirrhosis and mortality
among untreated patients over the study period is of concern, and
contrasts with the trends observed among treated patients; given
suggestions that patients even with low-level viremia derive
benefits from antiviral treatment, studies of additional indicators
for treatment (eg, aminotransferase levels or new biomarkers
such as quantitative hepatitis B surface antigen) may be war-
ranted. In a previous study, we found that antiviral treatment can
reduce risk for development of hepatocellular carcinoma by 83%
among patients with baseline hepatitis B virus (HBV) DNA
levels >20,000.7 A planned analysis will focus on the impact of
treatment indication status and access to care as risk factors for
these outcomes among patients with CHB.
In addition, while mortality did not increase for AAPI/
other or white patients, rates increased significantly for
African American patients over time. This is despite lower
rates of cirrhosis observed among African Americans versus
whites. It is possible this is attributable to higher overall all-
cause mortality among African Americans in general20 or
possible racial disparities in access to quality CHB care.2
However, it is a limitation of our analysis that we were not
able to assess this directly. Likewise, cirrhosis prevalence
was low among AAPI patients, despite high rates of CHB in
this community. It is possible that there are differences in
social determinants of health or natural history of CHB that
influence these observations, but because our study was not
designed to investigate risk factors for cirrhosis develop-
ment, we are limited in the interpretation of these findings.
Furthermore, independent of treatment status, we found
significant differences in APCs for cirrhosis across age cate-
gories. CHB patients aged 60 years and above had the highest
prevalence of cirrhosis and all-cause mortality; similar findings
have been reported among US veterans.21 Notably, although
the oldest patients in our cohort (60 y and above) had the
highest cirrhosis prevalence, the highest aAPC (indicating the
largest proportional increases) occurred among patients aged
50 to less than 60 years, at least 2 times faster than other age
groups; this suggests that CHB patients in this age group may
benefit from close monitoring. Rates of complications were
consistently higher in male patients than female. The 2:1 male:
female ratio remained across time, even as rate of cirrhosis
increased over the study period. Mortality was also higher
among male patients. This is consistent with a number of
studies of death among CHB patients.22–24
One of the strengths of this analysis was our use of
validated methods for classifying patients with cirrhosis to
ensure consistency across time. These methods, which
encompass a variety of observational data sources (liver
biopsy, transient elastography, FIB4 index, and ICD-9/10
diagnosis codes) address many of the limitations of relying
solely on diagnosis code-based data in an observational cohort.
Another strength of this analysis is the ongoing “dynamic”
cohort accrual over 5000 CHB patients from 4 large health
systems with a combined population of over 2 million adult
patients. We are aware of at least one cross-sectional study that
sought to estimate prevalence of cirrhosis among chronic HBV
patients seen in a US health care system during a similar time
period (2014-2016). They found an overall prevalence of
27.7%; rates differed by sex (lower among female than male
patients) but not by race. The authors of this study noted a
few limitations in their analysis, specifically that their
sample included largely uninsured and underinsured
patients drawn from a safety net health care system that
were referred for specialty gastroenterology care. These
differences likely underlie the higher rate of cirrhosis
observed among their population compared with our
own.4 We note that the dynamic sampling design
employed to generate our cohort is intended to increase
the generalizability of our results by enrolling a random
subset of CHB patients seen at our study sites.
Our study has several limitations. We used all-cause
mortality instead of liver-related mortality because a pre-
vious CHeCS analysis demonstrated that liver-related
mortality data is incomplete in routine-care settings.13,25
Although our analysis is based on ongoing “dynamic”
cohort accrual from health system populations, the cohort
has aged significantly over time; patients 60 years and above
made up only 7% of our 2006 cohort but 11% of the cohort
in 2016. However, we did adjust for age in our analysis and
found no indication of a qualitative interaction (change in
direction of the effect) between age and time. Likewise, we
were unable to confirm whether patients who did not receive
antiviral treatment were eligible for such treatment, given
the complexity of determining if and when treatment may be
indicated. In a previous analysis of CHeCS data through
2013, approximately one-third of patients were “treatment
eligible” (based on presence of immune-active disease and
cirrhosis), of whom 60% had been treated.26 Nevertheless,
this analysis was designed to describe overall temporal
changes in rates of CHB-related complications, rather than
the effect of treatment on individual patients, a topic that
has been previously covered. Finally, because our cohort
consists of individuals with at least some contact with the
health system, we are unable to estimate the prevalence of
outcomes in CHB-positive individuals who remain undiag-
nosed or those without ongoing contact with a health care
system. Such individuals are perhaps most at risk for poor
outcomes. In addition, our study is based primarily upon
health records data and may fail to capture factors that
potentially affect clinical outcomes, such as disease duration
or undiagnosed substance or alcohol misuse.
In conclusion, although the overall prevalence of cirrhosis
doubled from 2006 through 2016 among CHB patients in the
US-based CHeCS cohort, rates of all-cause mortality remained
consistently low overall. Considering that cirrhosis is an indi-
cation for antiviral treatment, rates were higher but increased
more slowly among patients who received antiviral treatment
compared with untreated patients. Notably, all-cause mortality
increased among untreated patients, but decreased among
treated patients. These results suggest that antiviral treatment
attenuates progression of cirrhosis and risk of death among
patients with CHB.
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